Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 4/20 | 0.52 |
| ▸ | F10 | P00742 | 2/20 | 0.52 |
| ▸ | MRGPRX4 | Q96LA9 | 5/20 | 0.48 |
| ▸ | MAOB | P27338 | 3/20 | 0.47 |
| ▸ | MAOA | P21397 | 2/20 | 0.47 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.46 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.46 |
| ▸ | GRM5 | P41594 | 2/20 | 0.43 |
| ▸ | CTRC | Q99895 | 1/20 | 0.42 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.42 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.42 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6553041 | 0.89 | F2 (0.67) | F2F10MRGPRX4GRM5CTRC | |
| SCHEMBL6553022 | 0.86 | F2 (0.57) | F2F10MAOBMAOACTRC | |
| SCHEMBL6552927 | 0.78 | F2 (0.68) | F2F10MAOBCTRC | |
| SCHEMBL6554419 | 0.78 | F2 (0.81) | F2F10CTRC | |
| Hydrochloric Acid SCHEMBL6554415 | 0.78 | F2 (0.80) | F2F10CTRC | |
| SCHEMBL1248693 | 0.76 | MAOB (0.66) | F10MRGPRX4MAOBMAOAFFAR1 | |
| SCHEMBL4701103 | 0.74 | FFAR1 (0.59) | MRGPRX4MAOBMAOAFFAR1FFAR4 | |
| SCHEMBL25232686 | 0.73 | NR4A2 (0.60) | F2MRGPRX4MAOBMAOAFFAR1 | |
| SCHEMBL30406905 | 0.73 | NR4A2 (0.60) | F2MRGPRX4MAOBMAOAFFAR1 | |
| SCHEMBL7435413 | 0.73 | F2 (0.74) | F2F10GRM5CTRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0883405-B1 | AMIDINO PROTEASE INHIBITORS | DIMENSIONAL PHARM INC (US) | 2004-02-25 | — | — | EP | disclosed |
| US-6414020-B2 | ANTIPROTEOLYTIC AMIDINO OR DERIVATIVE USEFUL FOR TREATING PENCREATITIS, THROMBOSIS, ISCHEMIA, STROKE, RESTENOSIS, EMPHYSEMA OR INFLAMMATION | 3- DIMENSIONAL PHARMACEUTICALS, INC. | 2002-07-02 | — | — | US | disclosed |
| US-20010025041-A1 | Amidino protease inhibitors | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2001-09-27 | — | — | US | disclosed |
| US-6281206-B1 | AMIDINO AND BENZAMIDINO COMPOUNDS | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2001-08-28 | — | — | US | disclosed |
| US-6225302-B1 | Amidino protease inhibitors | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2001-05-01 | — | — | US | disclosed |
| US-6133315-A | ADMINISTERING TO TREAT PANCREATITIS, THROMBOSIS, ISCHEMIA, STROKE, RESTENOSIS, EMPHYSEMA OR INFLAMMATION IN A MAMMAL; COMPOUNDS SUCH AS 2-CHLOROBENZENESULFONIC ACID 3-(3-AMIDINOPROPOXY)-5-METHYLPHENYL ESTER HYDROCHLORIDE | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2000-10-17 | — | — | US | disclosed |
| US-6034127-A | CARDIOVASCULAR DISORDERS; RESPIRATORY SYSTEM DISORDERS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2000-03-07 | — | — | US | disclosed |
| EP-0883405-A4 | AMIDINO PROTEASE INHIBITORS | DIMENSIONAL PHARM INC (US) | 1999-04-28 | — | — | EP | disclosed |
| EP-0883405-A1 | AMIDINO PROTEASE INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 1998-12-16 | — | — | EP | disclosed |
| WO-1997024135-A1 | AMIDINO PROTEASE INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 1997-07-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010025041-A1 | Amidino protease inhibitors | CTRL, PEPD, PRSS3 | F2 154/4885F10 296/4885MRGPRX4 357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.